XML Feed for RxPG News   Add RxPG News Headlines to My Yahoo!   Javascript Syndication for RxPG News

Research Health World General
 
  Home
 
 Latest Research
 Cancer
 Psychiatry
 Genetics
 Surgery
 Aging
 Ophthalmology
 Gynaecology
 Neurosciences
 Pharmacology
 Cardiology
 Obstetrics
 Infectious Diseases
 Respiratory Medicine
 Pathology
 Endocrinology
 Immunology
 Nephrology
 Gastroenterology
 Biotechnology
 Radiology
 Dermatology
 Microbiology
 Haematology
 Dental
 ENT
 Environment
 Embryology
 Orthopedics
 Metabolism
 Anaethesia
 Paediatrics
 Public Health
  Immunization
   Vaccination
 Urology
 Musculoskeletal
 Clinical Trials
 Physiology
 Biochemistry
 Cytology
 Traumatology
 Rheumatology
 
 Medical News
 Health
 Opinion
 Healthcare
 Professionals
 Launch
 Awards & Prizes
 
 Careers
 Medical
 Nursing
 Dental
 
 Special Topics
 Euthanasia
 Ethics
 Evolution
 Odd Medical News
 Feature
 
 World News
 Tsunami
 Epidemics
 Climate
 Business
Search

Last Updated: Aug 19th, 2006 - 22:18:38

Vaccination Channel
subscribe to Vaccination newsletter

Latest Research : Public Health : Immunization : Vaccination

   DISCUSS   |   EMAIL   |   PRINT
New Non-Invasive Vaccine Strategy May Offer Protection Against Tetanus and Anthrax
Jun 15, 2006, 18:03, Reviewed by: Dr. Harish Rao

"The nonreplicating E. coli vector overproducing an exogenous immunogen may foster the development of a new generation of vaccines that can be manufactured rapidly and administered noninvasively in a wide variety of disease settings,"

 
A new vaccine strategy using genetically engineered bacteria topically applied to the skin elicits an immune response to both tetanus and anthrax in animals say researchers from Vaxin Inc., Birmingham, Alabama. They report their findings in the June 2006 issue of the journal Infection and Immunity.

The new vaccine strategy described in this study consists of a topically applied vaccine containing live Escherichia coli bacteria that are genetically engineered to produce proteins associated with the bacteria that cause anthrax and tetanus. These compounds can be administered by nonmedical personnel. Past studies have shown the outer layer of the skin to be more immunocompetent than deep tissue and experts believe that self-applied painless vaccines will further increase the compliance rate.

In the study mice were administered a topical E. coli vectored vaccine and then challenged with tetanus cells and anthrax spores. Ninety percent of the vaccinated mice infected with tetanus survived, those that didn't receive the vaccine died within five days. Of the mice vaccinated and challenged with anthrax, only 44% survived, but when additional E. coli particles were added, the survival rate increased to 55%.

"The nonreplicating E. coli vector overproducing an exogenous immunogen may foster the development of a new generation of vaccines that can be manufactured rapidly and administered noninvasively in a wide variety of disease settings," say the researchers.
 

- J. Zhang, Z. Shi, F. Kong, E. Jex, Z. Huang, J.M. Watt, K.R. Van Kampen, D.C. Tang. 2006. Topical application of Escherichia coli-vectored vaccine as a simple method for eliciting protective immunity. Infection and Immunity, 74. 6: 3607-3617.
 

www.asm.org

 
Subscribe to Vaccination Newsletter
E-mail Address:

 



Related Vaccination News

New Non-Invasive Vaccine Strategy May Offer Protection Against Tetanus and Anthrax
Vaccine developed against dust mite allergy
Rotavirus vaccine will protect children against a major killer worldwide
World's First Plant-made Vaccine Registered
A solution to increase the efficacy of vaccines
Large Study Finds No Link Between Multiple Childhood Vaccinations And Subsequent Hospitalization For Nontargeted Diseases


For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

 

© Copyright 2004 onwards by RxPG Medical Solutions Private Limited
Contact Us